Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I Study of CNCT19 in Relapsed/Refractory Diffuse Non-Hodgkin Lymphoma
NCT04232826Phase 1Completed
- Sponsor
- Juventas Cell Therapy Ltd.
- Start
- Jan 2020
- Primary completion
- Jan 2021
- Modality
- CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of inaticabtagene autoleucel in diffuse large B-cell lymphoma (DLBCL), sponsored by Juventas Cell Therapy Ltd. Primary endpoints: Maximum Tolerated Dose, Dose Limiting Toxicity, and Recommended Phase II Dose at 28 days and Safety of CNCT19 therapy at 24 months. Started Jan 2020; status: completed.
02
Drugs
inaticabtagene autoleucel
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on NCT04232826.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04232826.